Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

PHASE3UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2023

Study Completion Date

December 31, 2023

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Inhaled Nitric Oxide

Trial Locations (17)

10003

Mount Sinai Beth Israel, New York

15212

Allegheny General Hospital, Pittsburgh

21201

University of Maryland Medical Center, Baltimore

27710

Duke University Medical Center, Durham

33331

Cleveland Clinic Florida, Weston

35294

University of Alabama at Birmingham, Birmingham

43221

Ohio State University, Wexner Medical Center, Columbus

44195

Cleveland Clinic, Cleveland

45267

UC Health University of Cincinnati, Cincinnati

75390

Fernando Torres, MD, Dallas

80045

University of Colorado Denver, Aurora

84107

Intermountain Medical Center, Murray

90073

West Los Angeles VA Healthcare Center, Los Angeles

T1Y6J4

Peter Lougheed Centre, Calgary

T6G2B7

University of Alberta Hospitals - MAHI, Edmonton

N6C2R5

Lawson Clinical Research Services, London

M5G2C4

University Health Network, Toronto

Sponsors
All Listed Sponsors
lead

Bellerophon Pulse Technologies

INDUSTRY